JMP Securities lowered the firm’s price target on Prothena to $81 from $83 and keeps an Outperform rating on the shares. Prothena reported Q3 results ahead of consensus estimates and reiterated that the Phase 1 SAD/MAD results for amyloid-beta antibody, PRX012, remain on track to be announced by the end of the year, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRTA:
- Prothena reports Q3 EPS 38c, consensus (32c)
- Prothena price target lowered to $43 from $60 at RBC Capital
- Biotech Alert: Searches spiking for these stocks today
- Prothena extends rally, up 14% to $50.42 after Bloomberg report
- Prothena trading resumes
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue